---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-170114"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:20:39.872401+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics stockholders elect three Class I directors, ratify KPMG, approve charter amendment

## Summary
- Elected Adrian R. Krainer (23.7M for, 8.0M withheld), Garry E. Menzel (26.0M for, 5.7M withheld), Julie Anne Smith (30.3M for, 1.3M withheld) as Class I directors.
- Ratified KPMG as independent auditor for FY 2023 with 35.5M for, 15.9K against, 987 abstentions.
- Approved amendment to Certificate of Incorporation: 27.0M for, 4.6M against, 4.7K abstentions.
- Broker non-votes of 3.8M shares recorded for director elections.

## SEC filing metadata
- accession: 0001193125-23-170114
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/d520719d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-170114
- JSON: https://secwatch.observer/filing/0001193125-23-170114.json
- Plain text: https://secwatch.observer/filing/0001193125-23-170114.txt

## Key facts
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors: Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith at the 2023-06-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Election of three Class I directors, Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: Nominees Shares For Shares Withheld/Abstaining Broker Non-Votes Adrian R. Krainer, Ph.D. 23,672,988 7,986,841 3,838,508 Garry E. Menzel, Ph.D. 25,992,037 5,667,792 3,838,508 Julie Anne Smith 30,318,661 1,341,168 3,838,508
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation at the 2023-06-13 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Approval of an amendment to the Company’s Certificate of Incorporation: Shares For Shares Against Shares Withheld/Abstaining 27,025,612 4,629,558 4,659
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Withheld/Abstaining 35,481,487 15,863 987
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.